

We are happy to send you this first DAD newsletter in 2010.

This is a welcoming opportunity for us to thank you all for the fantastic work and effort you have put into enrolling patients into D:A:D cohort III, completing events forms and responding to event queries. This remains of immense importance and have contributed to great improvements in knowledge and fine publications.

General information

A far more than expected number of patients was enrolled into D:A:D cohort III - actually there was more than 16,000 new patients. The total number of included HIV positive patients is now 49.000! This has been a huge work load for many and all your efforts are much appreciated.

Case report forms (CRF's)

In general you are all doing a fantastic job in completing forms.

But please keep in mind when filling out D:A:D CRF's:

- Please do not send two events on the same event form ie. ICP and MI, they should be send on two separate forms.
- Please do not send information on the same event form ie. ICP and MI, they should be send on two separate forms.
- Please do not send information on HgbA1c values. The diagnosis of diabetes mellitus (DM) is based on either two consecutive measurements of fasting blood glucoses or initiation of anti DM treatment

RECENT PUBLICATIONS:

1. [Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs \(D:A:D\) study.](#)

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J.J Infect Dis. 2010 Feb 1;201(3):318-30.PMID: 20039804

2. **Predicting the risk of cardiovascular disease in HIV-infected patients.**

N Friis-Møller, R Thiébaud, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, C A Sabin, JD Lundgren and MG Law for the D:A:D study group. European Journal of Cardiovascular Prevention and Rehabilitation. *In press*

-The event date on a NADM should always be the day of the histology rapport- not the day the clinical suspicion was raised. If no histology rapport is available the event date is that of the other possible surrogate measurements i.e. evidence from imaging technique(s).

- Please remember that we do not collect information on cancer relapse, metastasis, pre-cancer diagnosis like carcinoma in situ (CIS) and dysplasia, skin cancers (except malign melanoma) and AIDS defining cancers.

- Please remember that the new endpoints CLD, ESRD and NADM only include events after 01.01.04, i.e. a cancer diagnosis before this date will not be included.

New endpoint adds

This year we have added two changes to the new D:A:D endpoint forms.

- In the NADM form we have added a question on former exposure to radiation and/or chemotherapy.

- In the ESRD form documentation on dialysis now needs to be a minimum of 3 months (changed from 1 month).

As always updated CRF's can be found on the CHIP website.

Merger 11 and monitoring

We are in the middle of the monitoring process at the different sites. This year we are facing a tremendous challenge; to catch up with all the new end-points and

causes of death amongst HIV-positive individuals in the D:A:D study.

The Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group.

CJ Smith, C Sabin, JD Lundgren, R Thiebaut, R Weber, AD Monforte, O Kirk, N Friis-Moller, A Philips, P Reiss. WE Sadr, C Pradier, SW Worm.

AIDS. *In press*

4. Hepatitis B or C virus co-infections and risk of myocardial infarction in HIV-infected persons:

R Weber, C Sabin, P Reiss, S De Wit, SW. Worm, M Law, F Dabis, AD Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, JD Lundgren. The D:A:D Cohort Study. Antiviral Therapy. *In press.*

PRESENTATIONS:

17 th Conference on retroviruses and Opportunistic infections, San Francisco, February 2010

Oral Presentations

Rates of Cardiovascular Disease

Following Smoking Cessation in

Patients with HIV Infection: Results from the DAD Study. K Petoumenos, S Worm, P Reiss, S De Wit, A d'Arminio Monforte, N Friis-Moller, R Weber, P Mercie, C Pradier, J Lundgren on behalf

newly enrolled patients in cohort III. We are happy to inform you that despite of the above this is going very well. The success of this study is a consequence of the high quality of the data, and hence the awareness and meticulous work of numerous study personnel in the study. Thank you to all of you!

Database closing time

A reminder that the DAD database will close on the **15th of July 2010**. All outstanding D:A:D events should be in our hands before this date.

[Presentation](#)

Triglycerides and the risk of myocardial infarction in the DAD

study. S Worm, A Kamara, W El-Sadr, O Kirk, E Fontas, P Reiss, A Phillips, M Bruyand, A d'Arminio Monforte, M Law, R Weber, J Lundgren, C Sabin on behalf of the DAD study group.

[Presentation](#)